6-K ·Filed Jun 17, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001434265-26-000097
Notable filing: 6-K
Actionable Insight • Neutral

This filing is purely administrative with no trading implications. Monitor future 6-K filings for any material business developments such as pipeline updates, partnership changes, or financial results.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
GMAB ▲ +27.89% at T+60d
NEUTRAL call ✓ call won +27.89% · α vs SPY +24.74% · entry $25.39 → $32.47
Entry anchored
Jun 17, 11:30 AM ET
via exchange tick
T+1d
-0.47%
call -0.47% · α -1.25%
$25.27
settled 4mo ago
T+5d
+1.87%
call +1.87% · α +2.91%
$25.87
settled 3mo ago
T+20d
+14.14%
call +14.14% · α +12.82%
$28.98
settled 3mo ago
T+60d
+27.89%
call +27.89% · α +24.74%
$32.47
settled 18d ago

Price Chart

Loading chart...

Executive Summary

Genmab filed its updated Articles of Association (June 16, 2026) via a 6-K on June 17, 2026. The document is a routine corporate governance update covering standard provisions on share capital, warrant programs, board composition, and meeting procedures. No material financial, operational, or strategic changes were disclosed.

Key Facts

  • Share capital remains DKK 62,353,252 divided into shares of DKK 1 each.
  • Board authorized until March 12, 2029 to increase share capital by up to DKK 6,600,000 with or without pre-emption rights.
  • Multiple warrant programs for employees (excluding executive management) with caps of DKK 750,000 each under various general meeting authorizations.
  • Convertible debt instrument authorization up to DKK 3,000,000 nominal value until March 12, 2029.
  • Indemnification scheme for board members established through March 12, 2029.
  • Group language set to English; annual reports in English (and optionally Danish).

Financial Impact

No financial impact; routine governance filing with no new financial data.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000097
Document: gmab_20260617x6k.htm0001434265-26-000097
Document: 0001434265-26-000097-index-headers.html0001434265-26-000097
Document: 0001434265-26-000097-index.html0001434265-26-000097
Document: 0001434265-26-000097.txt0001434265-26-000097
13 reports for GMAB
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +26.50%Jun 29, 2026
Filters
Rows
Reports for GMAB — sortable, filterable
TypeNow
Sep 8, 2026
24d ago
6-K
NEUTRAL ★ 2/10
$33.53 $32.65▼ −2.62%▼ −1.96%$34.51 (+2.94%)
Aug 12, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$31.42 $34.11▲ +8.56%▲ +9.01%$34.51 (+9.85%)
Aug 11, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$30.85 $32.96▲ +6.84%▲ +7.24%$34.51 (+11.88%)
Aug 6, 2026
8w ago
6-K
BULLISH ★ 6/10
$29.83 $31.34▲ +5.06%▲ +3.85%$34.51 (+15.71%)
Jul 15, 2026
11w ago
6-K
NEUTRAL ★ 3/10
$29.08 $28.85▼ −0.79%▲ +0.19%$34.51 (+18.69%)
Jun 29, 2026
13w ago
6-K
BULLISH ★ 7/10
$27.47 $28.01▲ +1.97%▲ +1.36%$34.51 (+25.65%)
Jun 17, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$25.39 $25.87▲ +1.87%▲ +2.91%$34.51 (+35.94%)
Jun 16, 2026
15w ago
6-K
NEUTRAL ★ 1/10
$24.74 $25.94▲ +4.85%▲ +7.08%$34.51 (+39.51%)
Jun 15, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$24.58 $25.61▲ +4.19%▲ +5.57%$34.51 (+40.42%)
Jun 15, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$24.58 $25.61▲ +4.19%▲ +5.57%$34.51 (+40.42%)
Showing 10 of 13

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access